Table 1.
Characteristics of the study population. Data are presented as mean ± standard deviation, percentages, or median (interquartile range). FH = familial hypercholesterolemia, ASCVD = atherosclerotic cardiovascular disease, LDLR = low-density lipoprotein receptor, ApoB = apolipoprotein B
| Demographic characteristics | |
|---|---|
| N | 56 |
| Age, years | 56.38 ± 6.89 |
| Men, n(%) | 28 (50) |
| Smokers, n(%) | 12 (21.4) |
| ASCVD, n(%) | 26 (46.4) |
| FH genotype | |
| LDLR, n(%) | |
| 55 (98.2) | |
| ApoB, n(%) | 1 (1.8) |
| Mutation class | |
| Amino acid change, n(%) | |
| 30 (53.6) | |
| Null allele, n(%) | 26 (46.4) |
| FH phenotype | |
| Heterozygous FH, n(%) | 56 (100) |
| Treatment | |
| Duration of statin therapy, years | |
| 12 (2–20) | |
| Duration of ezetimibe therapy, years | 5 (1–7) |
| Antihypertensive therapy, n(%) | 22 (39.3) |
| High-intensity statin therapy | |
| Atorvastatin 40 mg, n(%) | 22 (39.3) |
| Rosuvastatin 20 mg, n(%) | 34 (60.7) |